Stryker (SYK) Q2 2026 Earnings Call Transcript
Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chair and Chief Executive Officer - Kevin A. Lobo Chief Financial Officer - Preston Wells Vice President of Investor Relations - Nick Mead TAKEAWAYS Organic Net Sales -- 9% growth, reflecting recovery from a previous cybersecurity incident and increased production to meet demand. Adjusted EPS -- $3.69, a 17.9% increase from the same quarter last year, reflecting improved gross margins and operational execution.
How this was made
The 30-second read
Why it matters
The most tradable elements are the updated full-year organic sales and adjusted EPS ranges, the stated drivers of gross and operating margin expansion, and the explicit risks from peripheral vascular supply disruption and continuing cyber remediation costs.
Market read
Traders can update models for Stryker based on the narrowed full-year guidance ranges, margin expansion drivers, and the quantified operational headwinds (backorders and cyber remediation costs).
What to watch
Investors may underweight the magnitude of lost sales from the manufacturing disruption and the cash flow timing of remediation and IT stabilization, which can affect near-term earnings quality despite strong reported guidance.
Background
This is a transcript-style summary of Stryker’s Q2 2026 earnings call, covering organic sales growth, adjusted profitability, and updated full-year guidance after a prior cybersecurity incident.
Ticker impact
Stryker reported Q2 2026 adjusted EPS of $3.69 and raised/narrowed full-year guidance to 8.3% to 9.3% organic sales and $14.95 to $15.10 adjusted EPS.
Near-term bias to the upside if investors focus on margin and guidance range tightening; downside risk if backorder losses or cyber remediation costs re-accelerate.
The article provides multiple concrete forward-looking datapoints (full-year organic sales range, adjusted EPS range, margin drivers) and also flags specific headwinds (lost sales from peripheral vascular backorder, ongoing cyber remediation costs).
Market effects
Signals continued demand strength in MedSurg and robotics-led orthopedics, while highlighting execution risks from manufacturing supply disruptions and cybersecurity remediation costs.
International organic sales growth (8.9%) led by Australia, New Zealand, Germany, and Canada supports a broader geographic demand narrative.
Reinforces the medical device sector’s ongoing shift toward ambulatory site-of-care and robotics adoption, with operational resilience as a key differentiator.
Counterpoint
The headline margin and guidance improvements may be partly offset by temporary lost sales from the peripheral vascular backorder and by ongoing cyber-related cost absorption that could pressure future quarters.
Key entities
- companyStryker
Reported Q2 2026 results and updated full-year guidance, citing margin expansion drivers and specific operational risks.
- executiveKevin A. Lobo
CEO who discussed recovery progress, production ramp, and product/platform priorities.
- executivePreston Wells
CFO who detailed results, guidance updates, and cyber-related cost considerations.
